RxDoctor Payments Data

Alexis Woods, MD

Internal Medicine · Phoenix, AZNPI 1043201486

Payments from drug & device makers

$1,091in general payments, 2019–2025

Across 55 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$162
  • AstraZeneca$152
  • GSK$146
  • Astellas Pharma US Inc$75
  • Amgen$73
  • Novartis$56
  • plus $427 from 14 others

What the payments were for

  • Food & beverage$1,091100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,091 in reported general payments places this provider in the 75th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$155,087
Medicare patients
447
Services billed
1,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide156$239,285
EliquisApixaban78$101,329
MounjaroTirzepatide60$64,927
CreonLipase/Protease/Amylase16$40,871
XareltoRivaroxaban34$40,650
TrulicityDulaglutide28$28,741
JanuviaSitagliptin Phosphate20$25,933
MyrbetriqMirabegron21$23,377
JardianceEmpagliflozin13$20,343
Breo ElliptaFluticasone/Vilanterol16$10,186
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$9,704
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$9,631
Ondansetron Hcl20$9,018
Repatha SureclickEvolocumab12$8,791
Mirabegron ErMirabegron13$6,670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$162$239,285156 claims
PfizerEliquis$43$101,32978 claims
Lilly USA, LLCMounjaro, Trulicity$56$93,66788 claims
MerckJanuvia$18$25,93320 claims
Astellas Pharma US IncMyrbetriq$75$23,37721 claims
Boehringer IngelheimJardiance$25$20,34313 claims
GSKBreo Ellipta$146$10,18616 claims
AstraZenecaSymbicort$152$4,62511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →